<DOC>
	<DOC>NCT00151255</DOC>
	<brief_summary>This is a study looking at all-trans retinoic acid in combination with standard induction and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia (AML).</brief_summary>
	<brief_title>All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>First Induction Therapy: - Cytarabine 100 mg/m² cont. i.v. days 1-5 - Idarubicin 12 mg/m² i.v. days 1, 3 - ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28 Second Induction Therapy: - Cytarabine 100 mg/m² cont. i.v. days 1-5 - Idarubicin 12 mg/m² i.v. days 1, 3 - ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28 First Consolidation Therapy: - Cytarabine 1000 mg/m² bid i.v. days 1-3 - Mitoxantrone 10 mg/m² i.v. days 2, 3 - ATRA 15 mg/m² p.o. days 4-28 Second Consolidation Therapy - Etoposide 100 mg/m² i.v. days 1-5 - Idarubicin 12 mg/m² i.v. days 1,3 - ATRA 15 mg/m² p.o. days 4-28</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Newly diagnosed AML defined according to the World Health Organization (WHO) classification (excluding acute promyelocytic leukemia [APL]) Aged &gt; 60 years All patients have to be informed about the character of the study. Written informed consent of each patient at study entry. Molecular and cytogenetical analyses on initial bone marrow and peripheral blood specimen have to be performed at the central reference laboratories. Bleeding independent of the AML Acute promyelocytic leukemia Uncontrolled infection Participation in a concurrent clinical study Insufficiency of the kidneys (creatinine &gt; 1.5 x upper normal serum level), of the liver (bilirubin, AST or AP &gt; 2 x upper normal serum level), severe obstruction or restrictive ventilation disorder, heart failure New York Heart Association [NYHA] III/IV Severe neurological or psychiatric disorder interfering with ability of giving informed consent No consent for the registration, storage and processing of data concerning the characteristics of the AML and the individual course Performance status WHO &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>age &gt; 60 years</keyword>
</DOC>